Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
GENFIT: OUTCOME OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 15, 2018 | ||
By: Nasdaq / GlobeNewswire - 18 Jun 2018 | Back to overview list |
|
GENFIT: OUTCOME OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 15, 2018 Lille (France), Cambridge (Massachusetts, United States), June 18, 2018 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced s the results of the voting by Shareholders at the Ordinary and Extraordinary Shareholders' Meeting which took place on June 15, 2018, in Lille, France. All resolutions were adopted by a large majority of at least 83.9% of the votes cast, except for resolution n°25 relating to issuing ordinary shares and/or securities giving access to the share capital of the Company for the benefit of the members of a company savings plan, in accordance with the Board of Director's recommendations, A total of 8,245,956 shares participated out of a total of 31,159,417 shares with voting rights, representing a quorum of 26.46%. Details of votes are available on the Company's website, in the investor's room (http://www.genfit.com/investors/documentation-center/). About GENFIT GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com Forward Looking Statement / Disclaimer CONTACT GENFIT | Jean-François Mouney - Chairman & CEO | +333 2016 4000 PRESS RELATIONS | Bruno Arabian | +336 8788 4726 Attachment |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |